Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT003 in moderate to severe allergic asthma
NCT01673672Phase 2Terminated
- Sponsor
- Cytos Biotechnology AG
- Start
- Nov 2012
- Primary completion
- May 2014
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Recombinant Protein Vaccines
- Countries
- 8
01
Overview
A Phase 2 trial of vidutolimod in allergic asthma, sponsored by Cytos Biotechnology AG. Started Nov 2012; status: terminated.
02
Drugs
vidutolimod
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT01673672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01673672.